drugset / Trial / NCT00933816
Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the recommended dose of the combination therapy of sorafenib with hepatic arterial infusion of low dose cisplatin and fluorouracil on patients with advanced hepatocellular carcinoma (Phase I), and to evaluate the efficacy of this combination therapy in the recommended dose (Phase II).
Timeline
- Start
- 2009-07
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 10 mg/m2 | Other |
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 170 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 330 mg/m2 | Other |
| Background | Sorafenib | Small molecule | 400 mg | Oral |